Takashi Sakaguchi1, Noboru Kusaka1, Tomoyasu Tsushima1, Toyoko Yamato2, Teruhisa Ohashi3, Bunzo Suyama4, Ryoji Arata1, Yasutomo Nasu1, Hiromi Kumon1
1Departments of Urology, Okayama University Medical School,
2Okayama City Hospital and
3Okayama Red-Cross Hospital, Okayama and
4Mitoyo General Hospital, Toyohama, Japan
Tóm tắt
AbstractPurpose:In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen‐independent prostate cancer, a prospective study was conducted using prostate‐specific antigen (PSA) as a primary end‐point.Methods:Nineteen Japanese men with stage D2 androgen‐independent prostate cancer were registered and treatment was started. After ruling out anti‐androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications.Results:Prostate‐specific antigen levels decreased in nine patients (50.0%); five (27.8%) showed a 50% or greater decrease and two (11.1%) showed an 80% or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2–27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8%). Of nine patients who had serial radiographic examinations with bone scan, three (33%) showed partial response, two (22%) were stable and four (44%) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection.Conclusion:Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen‐independent prostate cancer.
